The following HTML text is provided to enhance online
readability. Many aspects of typography translate only awkwardly to HTML.
Please use the page image
as the authoritative form to ensure accuracy.
Calling the Shots: Immunization Finance Policies and Practices
ters are especially important to meet school entry requirements for young children and to address the health needs of recent immigrants.
The appearance of new vaccines offering valuable and long-awaited protection from additional infectious diseases has caused states to draw on Section 317 funds during transitional periods. This situation occurred, for example, during the 11-month period after ACIP recommended the varicella vaccine and before a federal purchase contract was negotiated.
States vary in the way they respond to their residual needs. A few states rely solely on federal support, since all of the vaccines provided through their public health clinics are financed by Section 317. Others have used state revenues to purchase additional vaccines to meet their residual needs. States have broad discretion in determining whether to use state or federal funds to purchase vaccines, hire staff, or support contractual efforts. Some states use internal funds for personnel and thus rely more heavily on federal vaccine purchases; others draw on federal employees where possible to staff their immunization programs, and reserve their own funds for vaccine purchases and other programmatic needs.
State investments in immunization services appear to have increased during the 1990s, but these increases have not been at the same dramatic levels seen with the creation of VFC or the early growth in Section 317 budgets. States were more likely to extend their efforts through their investments in expanded Medicaid coverage, both by increasing vaccine administration fees and by broadening the base of clients served by Medicaid plans. Evidence is not available to indicate how the states invested in other types of immunization programs during this period.
Despite their cost-effectiveness, immunizations may be relatively costly at the point of service. Immunization costs vary greatly by vaccine. They reflect the cost of development and manufacturing, the competitive situation (i.e., if there are multiple suppliers of a vaccine, its price tends to be lower), the length of time a vaccine has been on the market, and the federal excise taxes that are levied on vaccines under the Childhood Vaccine Injury Act. The vaccine administration fee includes the actual injection, assessment of any possible risks or counterindications, disclosure of information to parents and individuals to ensure that immunizations are provided only following informed consent, and compliance with record-keeping and reporting requirements under state and federal law.
Two of these studies, the Current Population Survey March Supplement, conducted annually by the Census Bureau, and the Medical Expenditure Panel Survey (MEPS), conducted in 1996 by the Agency for Health Care Policy and Research (now the Agency for Healthcare Research and Quality), are the basis for estimates of general insurance coverage used in this report.